Indicated for: HIV-1 infection
Substance: lamivudine + zidovudine (nucleoside/nucleotide reverse transcriptase inhibitors)
ATC: J05AR01 (Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations)
The combination of lamivudine and zidovudine is used for the treatment of HIV-1 infection. Both substances are antiretrovirals that inhibit viral replication by interfering with reverse transcriptase.
The medication is taken orally, usually twice daily, as directed by a doctor. It is important to follow the treatment regimen to prevent the development of viral resistance.
Side effects may include nausea, anemia, fatigue, or muscle pain. In rare cases, lactic acidosis, myelosuppression, or severe allergic reactions may occur.
This combination is not recommended for patients with severe renal impairment, severe anemia, or hypersensitivity to any of the components.